Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.44 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14707083 | 1.00 | HTR2A (0.47) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 | |
| SCHEMBL14707008 | 1.00 | HTR2A (0.47) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 | |
| SCHEMBL15981159 | 0.89 | DHFR (0.41) | HTR2ADRD3ADRA1ADRD2HRH1 | |
| SCHEMBL14707071 | 0.87 | MEN1 (0.54) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 | |
| SCHEMBL29485914 | 0.87 | MEN1 (0.54) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 | |
| SCHEMBL15985175 | 0.85 | POLB (0.38) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 | |
| SCHEMBL15835892 | 0.80 | HTR7 (0.48) | DRD3DRD2HTR1ADRD4DRD5 | |
| SCHEMBL7832589 | 0.78 | SLC6A2 (0.51) | HTR2ASLC6A2SLC6A4ADRA1ASLC6A3 | |
| SCHEMBL11677590 | 0.77 | HRH3 (0.53) | SLC6A2SLC6A4CHRM2CHRM1DRD3 | |
| SCHEMBL11680549 | 0.77 | SLC6A2 (0.53) | HTR2ASLC6A2SLC6A4CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140057900-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057900-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013025882-A2 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2013-02-21 | — | — | WO | disclosed |
| US-6569849-B1 | N-Substituted azaheterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-0934306-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015546-A1 | N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-04-16 | — | — | WO | disclosed |
| EP-0107134-A1 | Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives | MILES LABORATORIES, INC. (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4029783-A | CARDIOTONIC, VASODILATION | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-06-14 | — | — | US | disclosed |
| US-3998810-A | CARDIAC AND CIRCULATORY ACTIVITY | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057900-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | HTR2A 792/4885SLC6A2 1310/4885SLC6A4 1538/4885 |
| US-20190135809-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | HTR2A 792/4885SLC6A2 1310/4885SLC6A4 1538/4885 |
| US-20170305906-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | HTR2A 792/4885SLC6A2 1310/4885SLC6A4 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.